Table 1.
Patients’ baseline characteristics
| Parameters | Total (N = 146) |
DCB (N = 120) |
NDB (N = 26) |
P value |
|---|---|---|---|---|
| Age(years) a | 64(56–69) | 0.346 | ||
| < 64 | 72 (49.3) | 57 (47.5) | 15 (57.7) | |
| ≥ 64 | 74 (50.7) | 63 (52.5) | 11 (42.3) | |
| Gender b | ||||
| Male | 111 (76.0) | 93 (77.5) | 18 (69.2) | 0.371 |
| Female | 35 (24.0) | 27 (22.5) | 8 (30.8) | |
| Histology b | ||||
| Non- Squamous | 101 (69.2) | 82 (68.3) | 19 (73.1) | 0.635 |
| Squamous | 45 (30.8) | 38 (31.7) | 7 (26.9) | |
| Stage b | ||||
| IIIB | 27 (18.5) | 25 (20.8) | 2 (7.7) | 0.118 |
| IV | 119 (81.5) | 95 (79.2) | 24 (92.3) | |
| Differentiation b | ||||
| Moderate | 13 (8.9) | 9 (7.5) | 4 (15.4) | 0.641 |
| Medium-Low | 18 (12.3) | 15 (12.5) | 3 (11.5) | |
| Low | 34 (23.3) | 28 (23.3) | 6 (23.1) | |
| NA | 81 (55.5) | 68 (56.7) | 13 (50.0) | |
| ECOG PS b | ||||
| 0 | 23 (15.8) | 18 (15.0) | 5 (19.2) | 0.185 |
| 1 | 108 (74.0) | 92 (76.7) | 16 (61.5) | |
| 2 | 15 (10.3) | 10 (8.3) | 5 (19.2) | |
| Smoking history b | ||||
| Never | 62 (42.5) | 48 (40.0) | 14 (53.8) | 0.195 |
| Now/Ever | 84 (57.5) | 72 (60.0) | 12 (46.2) | |
| Distant metastases b | ||||
| No | 27 (18.5) | 25 (20.8) | 2 (7.7) | 0.118 |
| Yes | 119 (81.5) | 95 (79.2) | 24 (92.3) | |
| Driver mutations b | ||||
| No | 113 (77.4) | 96 (80.0) | 17 (65.4) | 0.106 |
| Yes | 33 (22.6) | 24 (20.0) | 9 (34.6) | |
| PD-1 inhibitor type b | ||||
| Pembrolizumab | 47 (32.2) | 43 (35.8) | 4 (15.4) | 0.320 |
| Toripalimab | 18 (12.3) | 13 (10.8) | 5 (19.2) | |
| Camrelizumab | 31 (21.2) | 24 (20.0) | 7 (26.9) | |
| Sintilimab | 44 (30.1) | 35 (29.2) | 9 (34.6) | |
| Tislelizumab | 6 (4.1) | 5 (4.2) | 1 (3.8) | |
| Combination regimen b | ||||
| Monotherapy | 25 (17.1) | 19 (15.8) | 6 (23.1) | 0.787 |
| Chemotherapy | 89 (61.0) | 75 (62.5) | 14 (53.8) | |
| Anti-angiogenic therapy | 28 (19.2) | 23 (19.2) | 5 (19.2) | |
| Both | 4 (2.7) | 3 (2.5) | 1 (3.8) | |
| Drug regiment b | ||||
| 1st line | 62 (42.5) | 53 (44.2) | 9 (34.6) | 0.372 |
| ≥ 2nd line | 84 (57.5) | 67 (55.8) | 17 (65.4) | |
| Radiotherapy b | ||||
| No | 69 (47.3) | 53 (44.2) | 16 (61.5) | 0.108 |
| Yes | 77 (52.7) | 67 (55.8) | 10 (38.5) | |
ECOG PS Eastern Cooperative Oncology Group Performance Status, PD-1 Programmed cell death protein 1, CR Complete response, PR Partial response, SD Stable disease, PD Progressed disease
a Median and interquartile range (IQR)
b N (%)